圣达生物(603079) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 13.65% to CNY 44,653,784.35 for the year-to-date period[6] - Operating income for the year-to-date period increased by 5.44% to CNY 373,926,441.10 compared to the same period last year[6] - Basic earnings per share decreased by 13.04% to CNY 0.40[6] - Total revenue for Q3 2019 was ¥122,994,796.80, a decrease of 12.3% compared to ¥140,232,266.78 in Q3 2018[26] - Net profit for Q3 2019 was ¥8,541,744.68, a decline of 40.0% from ¥14,355,811.91 in Q3 2018[27] - The company reported a total profit of ¥11,538,743.21 for Q3 2019, a decrease of 29.0% compared to ¥16,417,328.65 in Q3 2018[27] - The total profit for the first three quarters of 2019 was approximately ¥24.88 million, down from ¥62.62 million in the same period of 2018, a decrease of about 60.3%[32] Assets and Liabilities - Total assets increased by 20.72% to CNY 1,512,242,976.08 compared to the end of the previous year[6] - Total current assets reached CNY 743,545,079.58, up from CNY 569,776,515.06, indicating a year-over-year increase of about 30.5%[20] - Total liabilities were reported at CNY 597,122,202.76, compared to CNY 424,293,547.93, which is an increase of approximately 40.7%[21] - Non-current assets totaled CNY 768,697,896.50, up from CNY 682,933,976.10, reflecting a growth of approximately 12.6%[20] - Total liabilities for Q3 2019 were ¥413,491,231.75, significantly higher than ¥185,113,481.39 in Q3 2018, indicating a rise of 123.0%[24] - Total assets as of Q3 2019 amounted to ¥1,250,771,076.40, compared to ¥954,610,826.55 in the same period last year, reflecting a growth of 31.0%[24] Cash Flow - The net cash flow from operating activities decreased by 50.86% to CNY 23,687,091.36 for the year-to-date period[6] - Cash received from government subsidies related to operating activities increased by 126.42% to ¥13,447,963.93[13] - Cash inflow from operating activities for the first nine months of 2019 was ¥267,916,044.51, slightly down from ¥271,922,881.20 in the same period of 2018[40] - Total cash inflow from financing activities in Q3 2019 reached ¥493,525,200.00, significantly higher than ¥149,900,000.00 in Q3 2018, indicating a strong increase in financing efforts[37] - The company reported a net cash outflow from investing activities of ¥96,711,775.02 in Q3 2019, compared to a smaller outflow of ¥38,550,460.57 in Q3 2018, indicating increased investment expenditures[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,823[9] - The largest shareholder, Zhejiang Shengda Group Co., Ltd., holds 28.94% of the shares, with 32,411,280 shares pledged[9] - The company's equity attributable to shareholders rose to CNY 881,438,073.72 from CNY 791,251,538.45, showing an increase of about 11.4%[21] Investments and Expenses - The company reported a loss from the disposal of non-current assets amounting to CNY 1,251,259.03 for the year-to-date period[8] - Research and development expenses for Q3 2019 increased to ¥8,277,832.20, up 82.5% from ¥4,540,722.90 in Q3 2018[26] - The company’s long-term assets, including construction in progress, increased by 46.69% to ¥240,262,705.00, indicating ongoing investment in growth initiatives[12] - The company issued convertible bonds, raising ¥291,525,200.00, which will be used for various projects including equity acquisition and production expansion[14] Financial Ratios - The weighted average return on equity decreased by 1.14 percentage points to 5.45%[6] - The company’s total liabilities to total assets ratio stands at approximately 33.9%[45]